🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Earlier today at #AANAM, 12-month efficacy and safety data from our Phase 2b trial of Descartes-08 in participants with #myastheniagravis were featured during an oral presentation delivered by Tuan Vu, M.D. View the presentation here: bit.ly/4joShrp

Reflecting on a successful #AANAM! Our team had a great time sharing insights with fellow researchers advancing important treatments in neurology. Learn more about our exciting updated Phase 2b results from our trial of Descartes-08 in #myastheniagravis: bit.ly/4lnk1yp

We loved seeing our team come together during recent Cartesian events! From laughs to meaningful connections, these moments remind us of what makes our culture so strong, united in our shared commitment to patients and expanding the reach of cell therapy to #autoimmunity.

Today we reported first quarter 2025 financial results and provided a business update. Full press release: bit.ly/42MsTGE #celltherapy #autoimmunity

We’re headed to The Netherlands for the @myastheniaorg International Conference to present recent exciting long-term results from Phase 2b trial of Descartes-08 in #myastheniagravis. Stop by our booth to learn more about how we're leveraging #celltherapy for #autoimmune diseases.

We are deeply committed to extending the potential of #celltherapy to patients with #autoimmune diseases, including #Lupus, a disease affecting ~1.5 million Americans. Learn about our Ph 2 trial of Descartes-08 in #SLE: bit.ly/3FtkEpy #LupusAwarenessMonth #WorldLupusDay

Happy Mother’s Day to the amazing moms at Cartesian! We celebrate and appreciate the unwavering love and support you provide, not just with your families, but in all that you contribute to our mission of expanding the reach of #celltherapy to patients with #autoimmune diseases.

Our team will be at the upcoming H.C. Wainwright & Co. BioConnect Investor Conference discussing upcoming expected updates in our pipeline of RNA cell therapies and next steps for our Phase 3 AURORA trial in #myastheniagravis. Details on how to tune in: bit.ly/3S1RukE

The first participant has been enrolled in our Phase 3 AURORA trial of Descartes-08 in patients with #myastheniagravis, marking a significant milestone in our mission to deliver a differentiated, durable treatment option to patients. Learn more: bit.ly/4kAFnai

At @myastheniaorg Conference we connected with global experts on new and exciting potential therapies for #MG, and presented positive long-term results from our Phase 2b trial of Descartes-08, with the first participant in our Phase 3 AURORA trial now enrolled. #MGAwarenessMonth

June is #PrideMonth. It’s a time to honor the legacy of the LGBTQ+ movement, mark progress, and renew the ongoing commitment and effort to build a more inclusive and equitable future. Cartesian celebrates our diversity and promotes dignity, safety, and rights for all.

We’re passionate about making a difference for the #myastheniagravis community, including those living with this #autoimmune disease, their loved ones, and the healthcare workers supporting their care. Learn more about this rare #neuromuscular disorder below. #MGAwarenessMonth

We heard from Allison Foss, Myasthenia Gravis Association (MGA) Executive Director and #MG patient, who shared powerful insights on life with this #autoimmune disease and the need for new treatment options, ensuring patients voices are heard. Thank you for sharing your story! #MGAwarenessMonth

Happy Father’s Day to the awesome dads of Cartesian! We recognize the dedication, care, and impact you provide both at home and in our advancement of #celltherapies for patients with #autoimmune diseases. Thank you for all that you do!

We had a great time at #BIO2025! Our CEO Carsten Brunn, PhD, spoke on a panel bringing together companies blazing new trails to bring targeted, durable therapies for #autoimmune diseases to patients in need by leveraging the potential of #celltherapy.

We honor the historical importance of #Juneteenth, marking the end of slavery in the U.S. We believe the unique experiences and perspectives of our team allow us to meaningfully serve our patients, and are committed to cultivating an inclusive workplace every day of the year.

We’re working to transform the #myastheniagravis treatment paradigm with a safe, flexible, and durable option, now enrolling in our Phase 3 AURORA trial. Hear from experts in the #MG therapeutic landscape on why continued innovation is essential. #MyastheniaGravisAwarenessMonth

At Cartesian, we have patients at the center of innovation. Which is why during #MGAwarenessMonth, we’re highlighting the potential of Descartes-08 to transform the current treatment landscape in #myastheniagravis, offering patients a safe, flexible, and durable treatment option.

Wrapping up June at Cartesian! Our culture is rooted in community and connection. We welcomed Allison Foss to share her #MG journey and how we can support patients and families. We capped the month with themed treats, team spirit, and an outing. Ending June energized by purpose!

Wishing our Cartesian team members and loved ones a safe and happy #IndependenceDay! Thank you to all the service members and their families, we’re grateful for all you do.